Abstract: Provided herein are synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof. Also provided herein are methods of treating and/or preventing Plasmodium infection and/or disease by administering the synthetic P. vivax antigens, antibodies and pharmaceutical formulations and vaccines thereof.
Type:
Grant
Filed:
November 24, 2020
Date of Patent:
October 17, 2023
Assignees:
UNIVERSITY OF SOUTH FLORIDA, WASHINGTON UNIVERSITY, CASE WESTERN RESERVE UNIVERSITY
Inventors:
John H. Adams, Christopher L. King, Niraj H. Tolia, Edwin Chen, Nichole Diane Salinas, Miriam Thankam George, Francis B. Ntumngia, Samantha Jones Barnes
Abstract: Provided are chimeric polypeptides that include one or more zinc finger motifs fused to a therapeutic peptide such as botulinum neurotoxins (BoNTs). The zinc finger motif may be located at the C-terminal side of the BoNT and the chimeric polypeptide can optionally include two or more such zinc finger motifs. It said the disclosed chimeric polypeptides can be efficiently delivered to a subject transdermally.
Abstract: The present invention describes a pharmaceutical composition whose active ingredient includes conjugates of membrane vesicles of Neisseria meningitidis and the GM3 ganglioside in a conjugation ratio in excess of proteins, has particular characteristics of size, surface charge and a morphology associated with nano-particulate systems that give it advantageous properties as an immunomodulator, because it induces a convenient and significant reduction of myeloid-derived suppressor cells that has an impact on the response of lymphocytes and on the survival of patients with tumors. The invention further discloses the use of the pharmaceutical composition disclosed in the treatment of cancer, particularly those cancers where the myeloid-derived suppressor cells (MDSCs) are high; as well as a method of treatment with said composition in cancer patients and a method to select those who will receive said treatment.
Type:
Grant
Filed:
December 17, 2018
Date of Patent:
September 26, 2023
Assignee:
Centro de Inmunología Molecular
Inventors:
Circe Mesa Pardillo, Liliana Oliver Ríos, Rydell Alvarez Arzola, Vladimir Peña Sánchez, Luis Enrique Fernández Molina, Anet Valdés Zayas, Maura Lisett Rábade Chediak, Lena Aguiar García, Lourdes Hernández de La Rosa, Audry Fernández Gómez, Leslie Pérez Ruíz, Camilo Rodríguez Rodríguez, Elias Antonio Gracia Medina, María Caridad Rubio Hernández, Orlando Valdés Guerrero, Idelmis Curbelo Haredia
Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.
Type:
Grant
Filed:
April 28, 2021
Date of Patent:
September 19, 2023
Assignees:
The United States of America, as Represented by the Secretary, Department of Health and Human Services, Sanaria Inc.
Inventors:
Robert Seder, Neville Kisalu, Azza Idris, Barbara Flynn, Stephen Hoffman
Abstract: In accordance with the invention, a novel gene translocation, (4p15, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of Sodium-dependent Phosphate Transporter Isoform NaPi-3b protein (SLC34A2) with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The SLC34A2-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides.
Abstract: An isolated polynucleotide including a promoter region derived from a bacterium of the genus Paracoccus, a recombinant host cell including the isolated polynucleotide, and a method of expressing a target gene by culturing a recombinant host cell comprising a polynucleotide comprising the promoter region and a target gene operably linked to the promoter region, under conditions in which the target gene is expressed.
Type:
Grant
Filed:
January 19, 2021
Date of Patent:
September 12, 2023
Assignee:
SAMSUNG ELECTRONICS CO., LTD.
Inventors:
Jae-Young Kim, Taeyong Kim, Seung Hoon Song, Woo Yong Shim, Yu Kyung Jung
Abstract: The present invention provides mutated fHbp polypeptides and fusion proteins comprising said mutated fHbp polypeptides that are useful as components of immunogenic compositions for immunizing against Neisseria meningitidis infection.
Abstract: The invention relates to gut microbiota profiles associated with response or resistance to treatments with ICB, in particular with anti-PD1 or anti PD-L1 or anti-PD-L2 antibodies. In particular, the invention pertains to a theranostic method for identifying good responders, to whom an anti-PD1 or anti PD-L1 or anti-PD-L2 can be administered, while a pre-treatment based on FMT and/or immunogenic probiotics is recommended to bad responders exhibiting a dysbiosis. In particular, the present invention pertains to Akkermansia muciniphila as the main commensal species distinguishing responders from progressors and its use alone or with E. hirae for the treatment of antibiotics or gut repertoire insufficiency-associated dysbiosis.
Type:
Grant
Filed:
December 22, 2017
Date of Patent:
June 27, 2023
Assignees:
INSTITUT GUSTAVE ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM, UNIVERSITE PARIS-SACLAY, Insitut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE)
Inventors:
Laurence Zitvogel, Bertrand Routy, Emmanuelle Le Chatelier
Abstract: Provided herein are polypeptides comprising up to 9 antigenic elements of ETEC virulence determinants: 7 CFA adhesins [CFA/I, CFA/II (CS1, CS2, CS3), CFA/IV (CS4, CS5, CS6)] expressed by the most prevalent and virulent ETEC strains, and 2 toxins expressed by all ETEC strains, were genetically fused together for CFA-toxoid fusion with proteins (CFA/I/II/IV-STatoxoid-LTtoxoid). Methods for making these polypeptides and their use in the treatment of ETEC related disease are also provided.
Type:
Grant
Filed:
April 27, 2020
Date of Patent:
June 27, 2023
Assignees:
The Johns Hopkins University, South Dakota State University
Abstract: The disclosure provides nucleic acids, and variants and fragments thereof, derived from strains of Bacillus thuringiensis encoding variant polypeptides having increased pesticidal activity against insect pests, including Lepidoptera and Coleopteran. Particular embodiments of the disclosure provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic acid of the embodiments. These compositions find use in methods for controlling pests, especially plant pests.
Abstract: The present invention relates to immunogenic polypeptides, immunogenic fragments thereof and compositions comprising same, for use in eliciting an immune response in a subject to a tick. The invention also provides for methods of using said compositions and polypeptides.
Type:
Grant
Filed:
February 6, 2018
Date of Patent:
April 11, 2023
Assignee:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
Inventors:
Alicja Tabor, Matthew Bellgard, Manuel Rodriguez Valle, Felicito Guerrero
Abstract: Bacillus strains, compositions and methods are disclosed for reducing growth of microorganisms in a feed. Bacillus strains, compositions and methods are disclosed for providing beneficial effects to animals, including but not limited to increasing performance of the animal.
Type:
Grant
Filed:
September 23, 2020
Date of Patent:
March 21, 2023
Assignee:
Church & Dwight Co., Inc.
Inventors:
Thomas Rehberger, John O'Neill, Alexandra Smith, Mari Ellen Davis, Jesse Thompson, Jennifer Schissel
Abstract: The present invention relates to an Agathobaculum sp. strain having prophylactic or therapeutic effects on autism spectrum disorders, and use thereof. When the intestinal microorganism Agathobaculum sp. strain of the present invention was orally administered to valproic acid (VPA)-induced autism model mice and BTBR autism model mice, the effects of remarkably improving autism spectrum disorders including repetitive behaviors, hyperactivity, social deficiency and cognitive/memory dysfunction of the mice were observed, as compared with a non-treated control. Accordingly, it may be usefully applied to foods, drugs, or feeds for preventing or treating autism spectrum disorders, and thus is very useful in the relevant industries.
Type:
Grant
Filed:
December 12, 2018
Date of Patent:
March 21, 2023
Assignee:
HEALTHBIOME
Inventors:
Byoung Chan Kim, Kyoung Shim Kim, Chul Ho Lee, Dong Ho Chang, Yong-Hoon Kim, Jung-Ran Noh, Dong Hui Choi, Jung Hwan Hwang, Jun Go, Jaehun Kim, Hye-Yeon Park, Yun-Jung Seo, Young-Kyoung Ryu, In-Bok Lee, Young Keun Choi, Jung-Hyeon Choi
Abstract: Method and compositions using transition metal salts and/or ammonium chloride to liberate toxins and other molecules from cyanobacteria, useful for assaying for total cyanobacterial toxins in lakes, reservoirs and other waters.
Abstract: Antigenic surface proteins expressed by Mycobacterium bovis under conditions that mimic the natural environment in a host are described. Use of the identified surface proteins in immunogenic compositions for immunization against M. bovis are also described. Nucleic acid molecules and plasmids encoding the M. bovis surface proteins are further described.
Abstract: Disclosed herein are isolated and purified Staphylococcus aureus bi-component leukocidin, referred to herein as LukAB, and its components LukA and LukB, antibodies specific to LukA, antibodies specific to LukB, therapeutic compositions containing LukA and/or LukB, or anti-LukA and/or anti-LukB antibodies, uses of the compositions to treat acute inflammatory conditions or S. aureus infection, methods for identifying inhibitors of LukAB-mediated cytotoxicity of human phagocytes, and methods for using LukAB as a marker to predict severity of S. aureus infection.
Abstract: The present application is generally directed to novel pneumococcal polypeptide antigens and nucleic acids encoding such antigens, and immunogenic compositions comprising such antigens for treating and preventing pneumococcal infection. The present invention further provides method of using the antigens to elicits an immune response (e.g., IL-17A response, a T cell-mediated and/or B-cell-mediated immune responses). The present invention also provides methods of prophylaxis and/or treatment of pneumococcal-mediated diseases, such as sepsis, comprising administering an immunogenic composition including one or more of a combination of pneumococcal antigens or functional fragments thereof as disclosed herein. In some embodiments, one or more pneumococcal antigens can be present in a polysaccharide conjugate. The compositions induce an anti-pneumococcus immune response when administered to a mammal.
Abstract: An object of the present invention is to provide a therapeutic composition for preventing, ameliorating, or treating metabolic syndrome. The present invention provides a composition for preventing, ameliorating, or treating metabolic syndrome, which composition contains Lactobacillus plantarum L-137.
Abstract: Embodiments of the present disclosure relate to chimeric antibodies which specifically bind to Borrelia decorin-binding protein A (DbpA) antigens and compositions or kits comprising such antibodies. The disclosure further relates to use of such antibodies in the detection of Borrelia sp. in samples, e.g., biological samples such as human blood and/or tissues of deer, ticks and other carriers of Borrelia. Embodiments of the disclosure further relate to diagnosis and/or therapy of Lyme disease using the chimeric antibodies and/or compositions containing the chimeric antibodies.
Abstract: Provided is a protein having Toxoplasma immunogenicity, the protein being a cyclophilin mutant protein and consisting of the amino acid sequence as shown in SED 2. Further provided is a nucleic acid that may encode a protein having Toxoplasma immunogenicity, which has the nucleic acid sequence as shown in SEQ ID NO. 1. Further provided is a vaccine, which is obtained by double-digesting a Toxoplasma antigen gene and then linking the same to a prokaryotic expression vector such as pET28a, and transforming the same into a prokaryotic expression engineering strain such as BL21(DE3), thereby inducing the high-efficiency expression thereof, wherein the inducing the high-efficiency expression thereof, wherein the purified protein is a soluble protein which maintains specific immunogenicity thereof.
Type:
Grant
Filed:
October 22, 2018
Date of Patent:
December 27, 2022
Inventors:
Feng Hou, Lili Cao, Pengtao Gong, Siming Li, Xingyuan Chen, He Ding, Dian Wang